国药一致(000028) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was CNY 73.42 billion, a decrease of 1.29% year-on-year[6] - Operating profit reached CNY 1.51 billion, an increase of 163.80% compared to the previous year[6] - Net profit attributable to shareholders was CNY 1.14 billion, up 76.80% year-on-year[6] - Basic earnings per share increased by 77.39% to CNY 2.04[6] - The weighted average return on equity rose by 2.59 percentage points to 6.26%[6] Segment Performance - The distribution segment generated CNY 53.32 billion in revenue, a year-on-year increase of 0.64%[6] - The retail segment (Guoda Pharmacy) reported revenue of CNY 20.98 billion, a decline of 6.16% year-on-year[7] - Guoda Pharmacy's net profit improved to a loss of CNY 0.22 billion, but showed a year-on-year increase of 80.36%[7] Strategic Focus - The company aims to focus on high-quality development and strategic adjustments in 2026[7] Asset Position - The total assets at the end of the reporting period were CNY 49.10 billion, an increase of 3.24% from the beginning of the period[4]